TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04630067
Drug: AZD3427
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.
Study: NCT02491463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
Study: NCT01451203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC)
Study: NCT01451203
Drug: methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral
Study: NCT01249404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.M. injection on day 1 (single treatment cycle)
Study: NCT00002600
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02043704
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Details covered in arm description.
Study: NCT01403415
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT01674868
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg daily for 90 days starting day 5-10 after stroke.
Study: NCT01674868
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects will take one pill po daily for 90 days.
Study: NCT00433979
Drug: antiretroviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: These antiretroviral drugs are a part of the participant's current drug regimen.
Study: NCT00081900
Drug: DENSPM )
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive DENSPM at an initial dose of 30mg/m\^2, then escalating to 120mg/m\^2, single IV infusion on D1,3,5,8,10,12 of every 28 days as one cycle, planned for 8 cycles if no withdrawn occur
Study: NCT03866824
Drug: injection of corticosteroids
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: intra-articular injection
Study: NCT06597903
Drug: NRL994
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the afternoon/evening before colonoscopy: 1 litre solution plus 0.5 litre clear fluid.~Day of colonoscopy: 1 litre solution plus at least up to 1 litre clear liquid.
Study: NCT01370499
Drug: LY2216684
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01933542
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo tablets identical to the chlorzoxazone tablets.
Study: NCT01211860
Drug: Diazoxide Choline Controlled-Release Tablet
Normalized name: diazoxide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCCR 290 mg once a day for 10 days
Study: NCT02452320
Drug: intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of 1000mg of intravenous acetaminophen or placebo every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
Study: NCT02452320
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to placebo will receive every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
Study: NCT03382639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luvadaxistat placebo-matching tablets.
Study: NCT02360358
Drug: Tiscover
Approvals — FDA: no, EMA: no, PMDA: no
Description: two step procedure, week 0 and week1. Dosage depends on wound size.
Study: NCT00987558
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03198559
Drug: Disulfiram, (National Drug Code) NDC 0378-4141-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study will provide open label disulfiram. Participants will take 2 grams (4x500mg tablets) of disulfiram per day for a total of 28 days
Study: NCT02812602
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch will be applied around the surgical wound about 20 minutes before removal of staples.
Study: NCT03230240
Drug: HIPEC
Normalized name: Hyperthermic Intraperitoneal Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: heated intraIP chemotherapy
Study: NCT02492321
Drug: EBI-005
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02492321
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03672006
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication administered to dwell in central venous catheter
Study: NCT02479022
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomised to receive a single dose of placebo orally as a comparator Insulin 320, at all dose levels.
Study: NCT02419443
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group
Study: NCT01430559
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7.5mg x2 once a day for 12 weeks
Study: NCT04686591
Drug: AZD9977 capsule 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capusles)
Study: NCT00504595
Drug: ACZ885 (investigational)
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The ACZ885 was supplied in 6 mL colorless glass vials each containing nominally 150 mg ACZ885 (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
Study: NCT00504595
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of ACZ885 was supplied in the form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
Study: NCT03016520
Drug: DWJ1392
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04589260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to be administered by oral inhalation
Study: NCT03252223
Drug: Recombinant Follicle Stimulating Hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: A modified dose-response study will be done using recombinant FSH (r-FSH), injected sc for 3 days at any one dose. r-FSH will be administered at weight-adjusted doses equivalent to 37.5, 75, and 150 IU based on an average weight of 70 kg, which approximates the weight of the average woman in the United States according to the Centers for Disease Control. Therefore, the actual dose of r-FSH will be 0.53 IU/kg for the 37.5 dose group. Accordingly, r-FSH will be repeated at doses of 1.1 IU/kg and 2.2 IU/kg that are equivalent to 75 and 150 IU for a 70 kg subject. Each FSH stimulation test will be assigned randomly and be separated by an interval of 8 weeks.
Study: NCT02557269
Drug: Prednisolone 5 mg
Normalized name: prednisolone 5 MG
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Per os - if needed (only in case of broncial obstruction)
Study: NCT02467504
Drug: hrIL-2 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
Study: NCT02467504
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid (oral administration)
Study: NCT01432470
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel for intravaginal use of identical appearance as active substance, once per day for two weeks followed by twice a week for ten weeks
Study: NCT03190304
Drug: Neprilysin
Approvals — FDA: no, EMA: no, PMDA: no
Description: To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
Study: NCT02208466
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive active fluoxetine (20mg) and take orally consecutively for 90 days.
Study: NCT02208466
Drug: Placebo Fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive placebo fluoxetine (sugar pills) and will take orally consecutively for 90 days.
Study: NCT03778281
Drug: Methoxyclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of metoclopramide 10mg, 3 times a day for three days, then evaluate the efficacy and side effects
Study: NCT03244280
Drug: MOB015B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical formulation
Study: NCT01843829
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02297867
Drug: ADSCs
Approvals — FDA: no, EMA: no, PMDA: no
Description: autologous ADSCs
Study: NCT04301557
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000mg/m\^2,Bid,P.O,D1-D14,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen, and two cycles in adjuvant treatment in Capecitabine regimen
Study: NCT02121535
Drug: T80/A5 mg FDC tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02121535
Drug: T80/A5 mg FDC tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Telmisartan 80 mg/ Amlodipine 5 mg FDC tablet
Study: NCT02121535
Drug: H12.5 mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02121535
Drug: T80/A5/H12.5 ng FDC tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Telmisartan 80 mg/Amlodipine 5 mg/HCTZ 12.5 mg FDC tablet
Study: NCT02121535
Drug: H12.5 mf tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: A HCTZ 12.5 mg tablet
Study: NCT02121535
Drug: T80/A5/H12.5 mg FDC tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01273012
Drug: Probiotic - Infloran
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug:Probiotic - Infloran (TM) 1 cap (1 billion CFU of L. acidophilus and 1 billion CFU of B. bifidum) PO bid or tid
Study: NCT02661789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of saline
Study: NCT00411229
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1,000 mg/m² twice daily. Film coated tablets of 500 mg, 150mg.
Study: NCT02911285
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills bid
Study: NCT01397409
Drug: AGN-150998
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-150998 Intravitreal injection.
Study: NCT02218424
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01013805
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1.~Leucovorin 200 mg/m2 Day 1 concurrent with Oxaliplatin over 2 hrs, then 2nd: 5-FU 400 mg/m2 bolus Day 1, then 3rd: 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1
Study: NCT01013805
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
Study: NCT00394173
Drug: DNK333
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNK333 25mg b.i.d. given orally for 4 weeks
Study: NCT00394173
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT01265511
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets given bid for 28 days
Study: NCT03763084
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients in the acetaminophen group, oral acetaminophen supplemented dexmedetomidine sedation will be provided after surgery.
Study: NCT03763084
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For patients in the control group, sufentanil supplemented dexmedetomidine sedation will be provided after surgery.
Study: NCT02760420
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
Study: NCT03574584
Drug: NNC0165-1562
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive NNC0165-1562 subcutaneous (s.c., under the skin) injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.
Study: NCT03574584
Drug: Placebo (NNC0165-1562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo (NNC0165-1562) s.c. injection(s) once-weekly for 20 weeks.
Study: NCT02873806
Drug: Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical antibiotic (tobramycin):~1 drop four (4) times per day in the study eye for one week (in cases of allergy or contraindication, Polytrim (polymyxin B sulfate + trimethoprim sulfate ophthalmic solution, USP, or equivalent) may be used as an alternative medication) .
Study: NCT03359811
Drug: Local Anesthetic Solution
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: A bolus or infusion of local anesthetic solution with or without the addition opioids given before surgical incision according to anesthesia provider's clinical judgment.
Study: NCT05106101
Drug: L-glutamine
Normalized name: L-Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-glutamine oral powder in 5 gram packet
Study: NCT03011931
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg Simvastatin given, Blood draw, Urine collection, Celiac serology testing, DNA sampling, Dietary review
Study: NCT03980054
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 400mg, orally once daily for one year
Study: NCT03959891
Drug: Aromatase Inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole is an aromatase inhibitor. This means it blocks the enzyme aromatase (found in the body's muscle, skin, breast and fat), which is used to convert androgens (hormones produced by the adrenal glands) into estrogen. In the absence of estrogen, tumors dependent on this hormone for growth will shrink.
Study: NCT00578331
Drug: Placebo Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 sprays each nostril twice daily
Study: NCT04859738
Drug: Benzokain Sprey
Normalized name: benzocaine Oral Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individuals who met the research criteria and signed the informed consent form were numbered according to the order in which they came to the hospital. Later, the numbered individuals were assigned to the study groups according to the randomization list created in the computer environment.~Benzocaine Spray was applied 60 seconds before to the area where the peripheral intravenous catheter will be applied to the patients in the Experiment II Group (Benzocaine Spray). After waiting 60 seconds, peripheral intravenous catheter application was performed.~The nurse responsible for data collection measured blood pressure, pulse rate and peripheral oxygen saturation values 5 minutes before and just after the application with a finger-type pulse oximeter.~After performing peripheral intravenous catheterization, the pain level felt by the individual during the procedure and the injection satisfaction level values were taken and recorded on the Case Report Form by the nurse.
Study: NCT03081858
Drug: TSD-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via intravesical instillation.
Study: NCT00000385
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT02130817
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4 followed by prednisone tapered to 10mg/d by day 30.,
Study: NCT03755258
Drug: GCK 100 mg + Placebo 200 mg
Normalized name: placebo 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCK 100 mg + Placebo 200 mg, oral, 12 weeks
Study: NCT03755258
Drug: GCK 200 mg + Placebo 100 mg
Normalized name: placebo 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCK 200 mg + Placebo 100 mg, oral, 12 weeks
Study: NCT03755258
Drug: GCK 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCK 300 mg, oral, 12 weeks
Study: NCT03755258
Drug: Placebo 300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 300mg, oral, 12 weeks
Study: NCT00830882
Drug: racemic salbutamol
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 puffs four times a day for 2 weeks
Study: NCT00830882
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 puffs four times a day for 2 weeks
Study: NCT00495313
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: COL-101, QD plus metronidazole
Study: NCT00495313
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg with metronidazole QD
Study: NCT01213888
Drug: Oral placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions
Study: NCT04508504
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL 0.9% Normal saline will be injected for the Placebo block
Study: NCT01864746
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles
Study: NCT04563845
Drug: GSK3640254
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3640254 will be administered.
Study: NCT04563845
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT02351622
Drug: Caffeic acid
Normalized name: CAFFEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of caffeic acid tablet 0.3g three times per day for 1 year
Study: NCT02351622
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pills manufactured to mimic caffeic acid tablet. Oral administration of placebo tablet 0.3g three times per day for 1 year.
Study: NCT01484119
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablets and capsules
Study: NCT01982942
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomly assigned to the placebo cohort will receive placebo oral capsule for 96 weeks.
Study: NCT02185040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral placebo daily
Study: NCT01667731
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily
Study: NCT03398759
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection during induction
Study: NCT00816712
Drug: Comparator: Testosterone 300 mg, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1 \& 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Testosterone 300 mg, Intramuscular injection.
Study: NCT00816712
Drug: Comparator: Testosterone 100 mg, Intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1 \& 7- Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Testosterone 100 mg, Intramuscular injection.
Study: NCT00816712
Drug: Comparator: Placebo given by Intramuscular Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1 \& 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Placebo given as intramuscular injection.
Study: NCT00402376
Drug: Pravastatin, Carvedilol, Perindopril
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02345070
Drug: SAR156597
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study: NCT02345070
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study: NCT01880320
Drug: CD0271 0.3% / CD1579 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01880320
Drug: CD0271 0.1% / CD1579 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02217020
Drug: FOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
Study: NCT02530580
Drug: 20 mg AZD7325
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 20 mg oral dose of AZD7325
Study: NCT02530580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose
Study: NCT04656262
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is formulated as coated tablets of 50mg for oral administration
Study: NCT04656262
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin is formulated as 60 mg/mq for infusional use (i.v use)